Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781985 | 0.86 | LMNA (0.48) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL8551105 | 0.86 | LMNA (0.63) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL1586881 | 0.80 | FFAR1 (0.63) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL8849741 | 0.77 | FFAR1 (0.67) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL4633969 | 0.76 | NPC1 (0.62) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL1586865 | 0.76 | LMNA (0.57) | LMNAL3MBTL1FFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL1205605 | 0.76 | LMNA (0.75) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL4884020 | 0.76 | CYP4F2 (0.55) | LMNAL3MBTL1FFAR1 | |
| SCHEMBL4879490 | 0.74 | CYP4F2 (0.50) | LMNAL3MBTL1FFAR1 | |
| SCHEMBL16695953 | 0.74 | CYP4F2 (0.62) | LMNAL3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9050339-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2616447-B1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-02-18 | — | — | EP | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | LMNA 2950/4885L3MBTL1 3259/4885FFAR1 1050/4885 |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | LMNA 2950/4885L3MBTL1 3259/4885FFAR1 1050/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | LMNA 2950/4885L3MBTL1 3259/4885FFAR1 1050/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | LMNA 2950/4885L3MBTL1 3259/4885FFAR1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.